These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
611 related articles for article (PubMed ID: 36990308)
41. Prediction of Preeclampsia Using the Soluble fms-Like Tyrosine Kinase 1 to Placental Growth Factor Ratio: A Prospective Cohort Study of Unselected Nulliparous Women. Sovio U; Gaccioli F; Cook E; Hund M; Charnock-Jones DS; Smith GC Hypertension; 2017 Apr; 69(4):731-738. PubMed ID: 28167687 [TBL] [Abstract][Full Text] [Related]
42. Ophthalmic artery Doppler in combination with other biomarkers in prediction of pre-eclampsia at 19-23 weeks' gestation. Sapantzoglou I; Wright A; Arozena MG; Campos RV; Charakida M; Nicolaides KH Ultrasound Obstet Gynecol; 2021 Jan; 57(1):75-83. PubMed ID: 33142353 [TBL] [Abstract][Full Text] [Related]
43. Stratification of pregnancy care based on risk of pre-eclampsia derived from biophysical and biochemical markers at 19-24 weeks' gestation. Litwinska M; Litwinska E; Astudillo A; Syngelaki A; Wright A; Nicolaides KH Ultrasound Obstet Gynecol; 2021 Sep; 58(3):360-368. PubMed ID: 33794058 [TBL] [Abstract][Full Text] [Related]
44. Association of first-trimester angiogenic factors with placental histological findings in late-onset preeclampsia. Triunfo S; Crovetto F; Crispi F; Rodriguez-Sureda V; Dominguez C; Nadal A; Peguero A; Gratacos E; Figueras F Placenta; 2016 Jun; 42():44-50. PubMed ID: 27238713 [TBL] [Abstract][Full Text] [Related]
45. Pregnancy outcomes in nulliparous women with positive first-trimester preterm preeclampsia screening test: the Great Obstetrical Syndromes cohort study. Boutin A; Guerby P; Gasse C; Tapp S; Bujold E Am J Obstet Gynecol; 2021 Feb; 224(2):204.e1-204.e7. PubMed ID: 32777265 [TBL] [Abstract][Full Text] [Related]
46. "Screening for small-for-gestational age neonates at early third trimester in a high-risk population for preeclampsia". Mula R; Meler E; García S; Albaigés G; Serra B; Scazzocchio E; Prats P BMC Pregnancy Childbirth; 2020 Sep; 20(1):563. PubMed ID: 32988372 [TBL] [Abstract][Full Text] [Related]
47. Changes in uterine artery Doppler velocimetry and circulating angiogenic factors in the first half of pregnancies delivering a small-for-gestational-age neonate. Triunfo S; Crovetto F; Rodriguez-Sureda V; Scazzocchio E; Crispi F; Dominguez C; Gratacos E; Figueras F Ultrasound Obstet Gynecol; 2017 Mar; 49(3):357-363. PubMed ID: 27241056 [TBL] [Abstract][Full Text] [Related]
48. Value of soluble fms-like tyrosine kinase-1/placental growth factor test in third trimester of pregnancy for predicting preeclampsia in asymptomatic women. Hanson E; Rull K; Ratnik K; Vaas P; Teesalu P; Laan M J Perinat Med; 2022 Sep; 50(7):939-946. PubMed ID: 35551712 [TBL] [Abstract][Full Text] [Related]
49. Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Chaiworapongsa T; Romero R; Korzeniewski SJ; Kusanovic JP; Soto E; Lam J; Dong Z; Than NG; Yeo L; Hernandez-Andrade E; Conde-Agudelo A; Hassan SS Am J Obstet Gynecol; 2013 Apr; 208(4):287.e1-287.e15. PubMed ID: 23333542 [TBL] [Abstract][Full Text] [Related]
50. Circulating angiogenic proteins in trisomy 13. Bdolah Y; Palomaki GE; Yaron Y; Bdolah-Abram T; Goldman M; Levine RJ; Sachs BP; Haddow JE; Karumanchi SA Am J Obstet Gynecol; 2006 Jan; 194(1):239-45. PubMed ID: 16389038 [TBL] [Abstract][Full Text] [Related]
51. The feasibility of soluble Fms-Like Tyrosine kinase-1 (sFLT-1) and Placental Growth Factor (PlGF) ratio biomarker in predicting preeclampsia and adverse pregnancy outcomes among medium to high risk mothers in Kuala Lumpur, Malaysia. Aminuddin NA; Sutan R; Mahdy ZA; Rahman RA; Nasuruddin DN PLoS One; 2022; 17(3):e0265080. PubMed ID: 35275947 [TBL] [Abstract][Full Text] [Related]
52. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Espinoza J; Romero R; Nien JK; Gomez R; Kusanovic JP; Gonçalves LF; Medina L; Edwin S; Hassan S; Carstens M; Gonzalez R Am J Obstet Gynecol; 2007 Apr; 196(4):326.e1-13. PubMed ID: 17403407 [TBL] [Abstract][Full Text] [Related]
53. Prediction of hypertensive disorders after screening at 36 weeks' gestation: comparison of angiogenic markers with competing-risks model. Schiattarella A; Magee LA; Wright A; Syngelaki A; Akolekar R; Von Dadelszen P; Nicolaides KH Ultrasound Obstet Gynecol; 2023 Sep; 62(3):345-352. PubMed ID: 37329494 [TBL] [Abstract][Full Text] [Related]
55. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Noori M; Donald AE; Angelakopoulou A; Hingorani AD; Williams DJ Circulation; 2010 Aug; 122(5):478-87. PubMed ID: 20644016 [TBL] [Abstract][Full Text] [Related]
56. Use of the angiogenic biomarker profile to risk stratify patients with fetal growth restriction. Arenas GA; Tang NY; Mueller A; Lopes Perdigao J; Kaur H; Abramowicz JS; Mussatt K; Yeo KJ; Rana S Am J Obstet Gynecol MFM; 2021 Jul; 3(4):100394. PubMed ID: 33991706 [TBL] [Abstract][Full Text] [Related]
57. Role of placental, fetal and maternal cardiovascular markers in predicting adverse outcome in women with suspected or confirmed pre-eclampsia. Reddy M; Palmer K; Rolnik DL; Wallace EM; Mol BW; Da Silva Costa F Ultrasound Obstet Gynecol; 2022 May; 59(5):596-605. PubMed ID: 34985800 [TBL] [Abstract][Full Text] [Related]